These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 35299965

  • 1. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
    Farhadi-Azar M, Behboudi-Gandevani S, Rahmati M, Mahboobifard F, Khalili Pouya E, Ramezani Tehrani F, Azizi F.
    Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
    [Abstract] [Full Text] [Related]

  • 2. The Hidden Link between Polycystic Ovary Syndrome and Kidney Stones: Finding from the Tehran Lipid and Glucose Study (TLGS).
    Rostami Dovom M, Rahmati M, Amanollahi Soudmand S, Ziaeefar P, Azizi F, Ramezani Tehrani F.
    Diagnostics (Basel); 2023 Aug 30; 13(17):. PubMed ID: 37685351
    [Abstract] [Full Text] [Related]

  • 3. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H, Tanir HM, Yildiz Z.
    Arch Gynecol Obstet; 2006 Jul 30; 274(4):227-32. PubMed ID: 16691383
    [Abstract] [Full Text] [Related]

  • 4. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran.
    Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F.
    Reprod Biol Endocrinol; 2014 Sep 16; 12():89. PubMed ID: 25224635
    [Abstract] [Full Text] [Related]

  • 5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE), Androgen Excess and PCOS Society (AES).
    Endocr Pract; 2015 Nov 16; 21(11):1291-300. PubMed ID: 26509855
    [Abstract] [Full Text] [Related]

  • 6. Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study.
    Skiba MA, Bell RJ, Herbert D, Garcia AM, Islam RM, Davis SR.
    Hum Reprod; 2021 May 17; 36(6):1611-1620. PubMed ID: 33846715
    [Abstract] [Full Text] [Related]

  • 7. Pre-polycystic ovary syndrome and polymenorrhoea as new facets of polycystic ovary syndrome (PCOS): Evidences from a single centre data set.
    Ganie MA, Rashid A, Baba MS, Zargar MA, Wani IA, Nisar S, Wani IA, Douhath S, Sriwastawa M, Geer MI, Asrar MM, Kutum R, Hassan S, Khan S, Rafi W, Bhat DA, Showkat W, Sahar T, Choh NA, Khurshid R, Mudassar S, Shah ZA, Shabir I, Sofi SA, Gupta N, Hafeez I, Sreenivas V.
    Clin Endocrinol (Oxf); 2023 Dec 17; 99(6):566-578. PubMed ID: 37656656
    [Abstract] [Full Text] [Related]

  • 8. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype.
    Legro RS, Chiu P, Kunselman AR, Bentley CM, Dodson WC, Dunaif A.
    J Clin Endocrinol Metab; 2005 May 17; 90(5):2571-9. PubMed ID: 15713728
    [Abstract] [Full Text] [Related]

  • 9. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis.
    Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO.
    Hum Reprod; 2016 Dec 17; 31(12):2841-2855. PubMed ID: 27664216
    [Abstract] [Full Text] [Related]

  • 10. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype.
    Bil E, Dilbaz B, Cirik DA, Ozelci R, Ozkaya E, Dilbaz S.
    J Obstet Gynaecol Res; 2016 Jul 17; 42(7):837-43. PubMed ID: 27071345
    [Abstract] [Full Text] [Related]

  • 11. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.
    Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H.
    Hum Reprod; 2012 Oct 17; 27(10):3067-73. PubMed ID: 22777527
    [Abstract] [Full Text] [Related]

  • 12. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.
    Fraissinet A, Robin G, Pigny P, Lefebvre T, Catteau-Jonard S, Dewailly D.
    Hum Reprod; 2017 Aug 01; 32(8):1716-1722. PubMed ID: 28854589
    [Abstract] [Full Text] [Related]

  • 13. The incidence of metabolic syndrome in adolescents with different phenotypes of PCOS.
    Altintas KZ, Dilbaz B, Cirik DA, Ozelci R, Zengin T, Erginay ON, Dilbaz S.
    Ginekol Pol; 2017 Aug 01; 88(6):289-295. PubMed ID: 28727126
    [Abstract] [Full Text] [Related]

  • 14. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria.
    Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T.
    Arch Gynecol Obstet; 2016 Feb 01; 293(2):447-56. PubMed ID: 26408006
    [Abstract] [Full Text] [Related]

  • 15. [Polycystic ovary syndrome: is there a rise in the prevalence?].
    Carmona-Ruiz IO, Saucedo-de la Llata E, Moraga-Sánchez MR, Romeu-Sarró A.
    Ginecol Obstet Mex; 2015 Dec 01; 83(12):750-9. PubMed ID: 27290799
    [Abstract] [Full Text] [Related]

  • 16. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome.
    Alebić MŠ, Stojanović N, Duhamel A, Dewailly D.
    Hum Reprod; 2015 Aug 01; 30(8):1927-33. PubMed ID: 26048913
    [Abstract] [Full Text] [Related]

  • 17. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.
    Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC.
    BJOG; 2006 Oct 01; 113(10):1210-7. PubMed ID: 16972863
    [Abstract] [Full Text] [Related]

  • 18. Analysis of 2-Arachidonoylglycerol Levels in Polycystic Ovary Syndrome in the Context of Hormonal and Metabolic Alterations and Across the Classical Phenotypes.
    Kabakchieva P, Gateva A, Hristova J, Georgiev T, Kamenov Z.
    Cannabis Cannabinoid Res; 2023 Aug 01; 8(4):634-641. PubMed ID: 35235418
    [Abstract] [Full Text] [Related]

  • 19. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.
    Azziz R.
    J Clin Endocrinol Metab; 2006 Mar 01; 91(3):781-5. PubMed ID: 16418211
    [Abstract] [Full Text] [Related]

  • 20. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
    Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T.
    Reprod Health; 2015 Jan 16; 12():7. PubMed ID: 25595199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.